Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 19Neoplasms 7Breast Neoplasms 5Pancreatic Neoplasms 4Hematologic Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Xanthogranuloma, Juvenile 1Thyroid Neoplasms 1Thrombocytosis 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Clear Cell 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Iodine-131 14trametinib 9dabrafenib 9Thyroidectomy 9Surgical Procedures, Operative 9lenvatinib 8Thyroxine 8Magnetic Resonance Spectroscopy 8pembrolizumab 7Paclitaxel 7anlotinib 6Thyrotropin Alfa 6selpercatinib 5Sorafenib 5Saline Solution 5Radiofrequency Ablation 5Everolimus 5pazopanib 4Vemurafenib 4Sunitinib 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4Dexmedetomidine 4Cyclophosphamide 4Biopsy, Fine-Needle 4Biopsy 4Bevacizumab 4apatinib 3Triiodothyronine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Neoplasms × cobimetinib × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡